NasdaqGM - Nasdaq Real Time Price USD

Zentalis Pharmaceuticals, Inc. (ZNTL)

1.2500

-0.0100

(-0.79%)

At close: May 19 at 4:00:00 PM EDT

1.2700

+0.02

+(1.60%)

After hours: May 19 at 5:24:19 PM EDT

Zentalis Pharmaceuticals First Quarter 2025 Earnings: US$0.67 loss per share (vs US$0.14 profit in 1Q 2024)

Zentalis Pharmaceuticals ( NASDAQ:ZNTL ) First Quarter 2025 Results Key Financial Results Net loss: US$48.3m (down from...

Simply Wall St. 3 days ago

ZNTL
-0.79%
Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress

First patient dosed in DENALI Part 2a clinical trial of azenosertib in patients with Cyclin E1+ PROC Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback $332.5 million cash, cash equivalents and marketable securities supports operational runway into late 2027 SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a pote

GlobeNewswire 5 days ago

ZNTL
-0.79%
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on May 1, 2025, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 14,000 shares of the Company’s common stock to one (1) newly hired employee.

GlobeNewswire 18 days ago

ZNTL
-0.79%
Pleasing Signs As A Number Of Insiders Buy Zentalis Pharmaceuticals Stock

Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...

Simply Wall St. 20 days ago

ZNTL
-0.79%
Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC

Phase 2 registration-intent trial enrolling Part 2a dose confirmation arms Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced tha

GlobeNewswire 21 days ago

ZNTL
-0.79%
Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting

SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that an abstract has been accepted for poster presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 to June 3, 2025 in Chicago, IL. The poster will include clinical d

GlobeNewswire 26 days ago

ZNTL
-0.79%
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on April 1, 2025, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 140,000 shares of the Company’s common stock to three (3) newly hired em

GlobeNewswire last month

ZNTL
-0.79%
Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from registration-intent DENALI Part 2 anticipated by year end 2026 Strengthened management team to support execution of highly focused strategy $371.1 million cash, cash equivalents and marketable securities balance as of December 31, 2024, with projected cash runway into late 2027 SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- Zentalis®

GlobeNewswire last month

ZNTL
-0.79%
Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

One poster demonstrating cell-free DNA molecular response as a potential surrogate endpoint to measure clinical efficacy of azenosertib in patients with high-grade serous ovarian cancer (HGSOC) Three additional posters highlighting the potential for broad therapeutic applications of azenosertib as both a single agent and combination therapy as shown in preclinical models SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutic

GlobeNewswire last month

ZNTL
-0.79%
Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer

Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer (PROC) and continues to demonstrate an objective response rate (ORR) of ~35% in response-evaluable patients On track to initiate Part 2 of the ongoing DENALI clinical trial in 1H 2025, with registration-intent topline data anticipated by year end 2026 Company also presents preclinical combination data of azenosertib with microtubule

GlobeNewswire 2 months ago

ZNTL
-0.79%
Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer

Updated clinical data from ongoing DENALI clinical trial of azenosertib in patients with PROC Preclinical data of azenosertib demonstrating antitumor effects with microtubule inhibitor based ADCs SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced multiple presentations

GlobeNewswire 2 months ago

ZNTL
-0.79%
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that members of the management team will participate in the following upcoming investor conferences: TD Cowen 45th Annual Health Care Conference, Boston, MA. Fireside discussion, March 3, 2025, 11:50 a.m. ET.Leerink Glo

GlobeNewswire 2 months ago

ZNTL
-0.79%
Zentalis Pharmaceuticals (ZNTL): Among Cheapest Stocks Insiders Are Buying Recently

We recently published a list of 10 Cheapest Stocks Insiders Are Buying Recently. In this article, we are going to take a look at where Zentalis Pharmaceuticals (NASDAQ:ZNTL) stands against other cheapest stocks that insiders are buying recently. Why should we be interested in affordable stocks? Some investors like to look for cheaper stocks in […]

Insider Monkey 2 months ago

ZNTL
-0.79%
Zentalis Pharmaceuticals (ZNTL) Loses -46.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Zentalis Pharmaceuticals (ZNTL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks 3 months ago

ZNTL
-0.79%
Zentalis price target lowered to $10 from $20 at Oppenheimer

Oppenheimer analyst Matthew Biegler lowered the firm’s price target on Zentalis (ZNTL) to $10 from $20 and keeps an Outperform rating on the shares. The company this morning presented data for the first time in over two years, “so there’s a lot to unpack,” the analyst tells investors in a research note. The bar is 15%, and azenosertib consistently doubles that in ovarian cancer, particularly among CCNE1-high subtypes, contends the firm. Opco believes investors are “squabbling” that the duration

TipRanks 3 months ago

ZNTL
-0.79%
Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer

Results from DENALI Part 1b show an Objective Response Rate (ORR) of ~35% in response-evaluable, heavily-pretreated patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Across monotherapy cohorts in key clinical studies, well-characterized safety and tolerability profile shows no new safety signals Company aligned with FDA on seamless study design for DENALI Part 2 in patients with Cyclin E1+ PROC; study expected to begin 1H 2025 Topline data from registration-intent DENALI Part 2 a

GlobeNewswire 3 months ago

ZNTL
-0.79%
Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development

Extended cash runway into late 2027, beyond a potentially registration-enabling azenosertib data readout from DENALI Part 2 Planned workforce reduction of approximately 40% of employees Corporate event to be held on January 29, 2025 at 8:00am ET to provide key updates on azenosertib clinical data, development and regulatory path SAN DIEGO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinic

GlobeNewswire 3 months ago

ZNTL
-0.79%
US Exchange Penny Stocks To Watch In January 2025

The U.S. stock market has recently experienced volatility, with the Nasdaq Composite and S&P 500 indices declining sharply due to concerns over China's advancements in artificial intelligence. Amidst these fluctuations, investors are increasingly exploring diverse opportunities, including penny stocks—an investment area that continues to intrigue despite its somewhat outdated terminology. These stocks often represent smaller or newer companies and can offer a blend of affordability and growth...

Simply Wall St. 3 months ago

VNDA

MNOV

ZNTL
-0.79%
Zentalis Pharma Says FDA Grants Fast Track Status on Azenosertib Cancer Drug Candidate

Zentalis Pharmaceuticals (ZNTL) said Thursday the US Food and Drug Administration granted fast track

PREMIUM
MT Newswires 4 months ago

ZNTL
-0.79%
Zentalis Pharmaceuticals (ZNTL) Upgraded to Strong Buy: What Does It Mean for the Stock?

Zentalis Pharmaceuticals (ZNTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks 4 months ago

ZNTL
-0.79%

Performance Overview

Return	ZNTL	S&P 500 (^GSPC)
YTD	-58.75%	+1.39%
1-Year	-89.64%	+12.45%
3-Year	-94.73%	+52.88%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Zentalis Pharmaceuticals, Inc. (ZNTL)

Zentalis Pharmaceuticals First Quarter 2025 Earnings: US$0.67 loss per share (vs US$0.14 profit in 1Q 2024)

Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Pleasing Signs As A Number Of Insiders Buy Zentalis Pharmaceuticals Stock

Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC

Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer

Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

Zentalis Pharmaceuticals (ZNTL): Among Cheapest Stocks Insiders Are Buying Recently

Zentalis Pharmaceuticals (ZNTL) Loses -46.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zentalis price target lowered to $10 from $20 at Oppenheimer

Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer

Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development

US Exchange Penny Stocks To Watch In January 2025

Zentalis Pharma Says FDA Grants Fast Track Status on Azenosertib Cancer Drug Candidate

Zentalis Pharmaceuticals (ZNTL) Upgraded to Strong Buy: What Does It Mean for the Stock?

Performance Overview